Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III has been inspected by the United States Food and Drug Administration (USFDA). The inspection was conducted from January 27 to February 06, 2026 and concluded with 11 observations. The observations are procedural in nature. The Unit-III is a Formulation manufacturing facility of Eugia Pharma Specialities situated in Telangana.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
